ReviewCurrent medicinal chemistry2026
lncRNAs and circRNAs: Emerging Players in Pediatric Medulloblastoma Pathology.
Review in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Noncoding RNAs in Pediatric Solid Tumors: Advances in Understanding and Critical Knowledge Gaps.Cells · 2026Review
- Hsa_circ_PCNT sponges hsa-miR-133b to promote SHH medulloblastoma via TAGLN2.Cellular and molecular life sciences : CMLS · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medulloblastomas (MBs) are the most common malignant brain tumors in children, marked by aggressive growth, molecular heterogeneity, and a high propensity for cerebrospinal dissemination. Despite advancements in conventional treatments - surgery, chemotherapy, and radiation therapy-substantial challenges persist, including debilitating long-term toxicities and emerging resistance to therapy. This review examines the multifaceted roles of non-coding RNAs (ncRNAs) - particularly long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) - in pediatric medulloblastoma pathogenesis, diagnosis, and therapeutic targeting. NcRNAs exert robust regulatory effects on gene expression by modulating signaling pathways, acting as miRNA sponges, and controlling the expression of oncogenic or tumor-suppressive genes. In this study, we focus on notable examples of lncRNAs (e.g., HOTAIR, TP73-AS1) and circRNAs (e.g., circ-SKA3, circ_63706) implicated in fundamental oncogenic processes, such as cell proliferation, apoptosis, metastasis, and stem cell maintenance. We also discuss their subgroup-specific roles, emphasizing high-risk groups, such as Sonic Hedgehog (SHH) and Group 3 medulloblastomas. In parallel, we explore the potential of ncRNAs to serve as diagnostic/prognostic biomarkers, given their tissue-specific expression, stability, and detectability in biological fluids like the Cerebrospinal Fluid (CSF). Finally, we review emerging therapeutic strategies, including antisense oligonucleotides, RNA sponges, and CRISPR-based editing, aimed at disrupting oncogenic ncRNA functions or reinforcing tumor-suppressive pathways. While these strategies hold promise, major hurdles include functional redundancy, optimizing in vivo delivery, and mitigating off-target effects. By detailing these challenges and outlining future research directions, this review underscores the revolutionary potential of ncRNA-focused diagnostics and therapies for managing pediatric medulloblastomas, offering new paths for improving survival outcomes and quality of life in affected children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.